Anti-inflammatory actions of an N-terminal peptide from human lipocortin 1

G. Cirino, C. Cicala, L. Sorrentino, G. Ciliberto, G. Arpaia, M. Perretti, R. J. Flower

Research output: Contribution to journalArticlepeer-review


An acetylated polypeptide corresponding to residues 2-26 of human lipocortin 1 was synthesized and the anti-inflammatory activity assessed in three models of acute inflammation in rat and mouse. In the carrageenin rat paw oedema test, the peptide produced a maximal inhibition of approximately 41% at the 3 h time point with a 10 μg dose. When rat paw oedema was induced by the injection of venom phospholipase A2, the peptide produced a significant inhibition (31%) at the top dose of 20 μg per paw. In the mouse air-pouch model, systemic treatment with the peptide produced a dramatic reduction in cytokine-induced leukocyte migration with an ID50 of approximately 40 μg per mouse. The N-terminal peptide 2-26 shares the actions of lipocortin 1 in these acute models of inflammation.

Original languageEnglish
Pages (from-to)573-574
Number of pages2
JournalBritish Journal of Pharmacology
Issue number3
Publication statusPublished - 1993


  • Acute inflammation
  • Anti-inflammatory actions
  • Lipocortin 1/annexin 1
  • N-terminus

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'Anti-inflammatory actions of an N-terminal peptide from human lipocortin 1'. Together they form a unique fingerprint.

Cite this